Since 1993, clinicians have used the International Prognostic Index (IPI) 4 to characterize prognosis in aggressive NHL based on five clinical factors: age, stage, the number of extranodal sites, performance status, and LDH. However, in the past two decades, tremendous effort has been made to identify unique DLBCL subtypes by cell of origin (COO) and molecular features, which can be used independently of the IPI to identify high-risk disease and predict failure of up-front R-CHOP and/or ASCT at the time of relapse. In a parallel timeframe, multiple clinical studies have explored differential approaches to up-front treatment and treatment of relapsed disease based on disease subtype and our evolving understanding of the underlying disease pathogenesis of each subtype. Most recently, next-generation sequencing and comprehensive genomic analysis has allowed us to further subclassify this disease by recurrent, high-frequency mutations, which provides a solid foundation for the development of novel targeted approaches.
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| DIAGNOSIS
The diagnosis of DLBCL is ideally made from an excisional biopsy of an abnormally enlarged, suspicious appearing lymph node upon clinical examination and radiographic imaging. This allows for the largest amount of tissue to be reviewed by pathology and avoids sampling error and false negatives, which can happen with fine needle aspiration or core biopsy in a highly heterogeneous lymph node tissue environment.
DLBCL can frequently involve extranodal sites, including the kidneys, adrenal gland, brain, bones, and other soft tissues. Careful requirements must be made in each patient to obtain a biopsy that is the least invasive and yet provides sufficient tissue. Positron emission tomographycomputed tomography can be used to determine the sites of disease with the highest standardized uptake value (SUV) and possibly the most aggressive disease and to notify the preferred site of biopsy. Morphologically, DLBCL is characterized by a diffuse infiltration of mediumto-large cells with large nucleoli and abundant cytoplasm, which disrupt and efface the underlying architecture of the involved lymph node. The cells typically express pan-B-cell antigens, including CD19, CD20, CD22, CD79a, and CD45. The majority of the cells also express surface immunoglobulin (IG). 8 Approximately 14% of cases express CD30, which can portend to a favorable prognosis.
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| Cell of origin
In 2000, Alizadeh and colleagues used gene expression profiling (GEP) of 96 normal and DLBCL lymphocytes to identify three unique genetic signatures that portended to three different subtypes of disease based on COO. These include the germinal center B-cell (GCB)-like subtype, which resembles the GEP of normal GCBs, the activated B-cell (ABC)-like subtype, which resemble normal ABCs, and unclassifiable disease in the remaining 10%-15% of samples. 11 Although originally identified by GEP, this assay has had limited clinical adoption as yet because of high cost and the need for fresh frozen tissue. In clinical practice, immunohistochemistry (IHC) algorithms such as the Hans and Tally methods are used to identify COO, with variable concordance to GEP. 12, 13 Recently, more novel platforms such as Lymph2Cx allow for digital GEP on fixed, paraffinembedded tissue and have shown a greater concordance with GEP than IHC. 14, 15 This platform currently remains useful in the research setting, and it has not yet been adapted for clinical use. Given the wide adoption of IHC algorithms to assess COO, DLBCL is most commonly classified into GCB DLBCL and non-GCB DLBCL. Although being a misnomer, the non-GCB DLBCL contains ABC DLBCL (which do originate from the germinal center) and the previously unclassifiable disease per GEP. When disease is assessed by GEP, these three distinct subcategories remain.
| Molecular features
In parallel to COO studies, the subtypes of DLBCL based on molecular features have also been found to have prognostic impacts. c-MYC is a proto-oncogene in chromosome 8q24 and encodes a transcription fac- 
| RISK STRATIFICATION
A combination of clinical factors, COO, and molecular studies are used to predict prognosis in DLBCL.
| Clinical factors
The IPI has been used since 1993 to predict prognosis in aggressive NHL treated with doxorubicin-containing regimens. 4 This has been validated in the rituximab era (R-IPI) and in patients <60 years of age (age-adjusted IPI). 23 It has also been expanded to include the more granular information about each of these variables in the recent NCCN-IPI. 24 In the most commonly used IPI, patients with a score of 0-1, 2, 3, and 4-5 had a 3-year overall survival (OS) of 91%, 81%, 65%, and 59%, respectively. 25 
| Cell of origin
Multiple studies have shown that patients with the ABC disease subtype have significantly poorer outcomes to standard up-front rituximabcontaining CI compared to GCB disease. 12, 14, 26 In a study of 157 de novo DLBCL cases treated with up-front rituximab containing CI, patients with the ABC subtype as identified by GEP had a 5-year progression-free survival (PFS) of 31% compared to 76% in GCB disease, which translated to an inferior 5-year OS (45% vs 80%). 12 Similarly, in a study of 344 patients with de novo DLBCL treated with R-CHOP that used the Lymph2Cx assay on the paraffin-embedded tissue to identify COO, the 5-year PFS and 5-year OS was 48% and 56%, respectively, in ABC disease, compared to 73% and 78% in GCB disease. 14 Although a phase Ib study of ibrutinib + R-CHOP showed that the combination was tolerable and had high responses in both GCB (5/7) and ABC disease (2/2 patients), 46 the phase III PHOENIX study of this combination for stage I-IV non-GCB DLBCL as identified by IHC and ABC DLBCL as identified by GEP was stopped early by Jannsen in July 2018 because it did not meet its primary PFS endpoint [NCT01855750].
These data were presented at the American Society of Hematology (ASH) 2018 meeting, while in the whole study, the population outcomes of R-CHOP with and without ibrutinib were not significantly different, an unplanned subset analysis suggested benefits in PFS, event-free survival (EFS), and OS in patients <60. It appeared that increased antilymphoma activity was offset by a higher frequency of toxicities abrogating benefits particularly in older patients.
Similarly, in an early phase trial of bortezomib + R-CHOP, the combination was tolerable and suggested improvements in PFS and OS in non-GCB disease (as identified by IHC), but these results could not be confirmed in larger phase II (PYRAMID) and III (ReMoDL-B) studies. [47] [48] [49] A phase II study of lenalidomide in addition to R-CHOP in untreated DLBCL showed an impressive overall response rate (ORR) of 98% (80% CR) and similar response rates between GCB and non-GCB disease (as identified by IHC), suggesting that lenalidomide can overcome the negative prognostic impact of non-GCB disease. 50 
| Treatment options in DLBCL by molecular features-up-front therapy
Despite knowledge that up-front R-CHOP produces poor long-term outcomes in DHL/THL, the rarity of this entity has precluded robust prospective data to help establish an optimal induction regimen. Multiple retrospective studies have suggested that intensification of up-front CI may be superior to R-CHOP, which was confirmed in a systemic review and meta-analysis of 394 patients from 11 studies. 36, 51, 52 Overall, a multicenter retrospective study of 311 patients with previously untreated DHL who were treated with induction therapy ± ASCT, at a median follow-up of 23 months, the median PFS of those receiving R-CHOP was 7.8 months compared to 21.6 months with more intensive up-front CI strategies, such as R-EPOCH, R-CODOX-M/IVAC, and R-HyperCVAD. 36 The meta-analysis by Howlett et al. suggested a superior PFS to R-EPOCH compared to R-CHOP and other intensified regimens, which has led to widespread adoption of intensified frontline CI in this population, but this needs to be validated in a prospective manner. The CALGB/Alliance 50303 phase III trial of DA-EPOCH showed no differences in EFS or OS in the DLBCL population as a whole, but subset analysis by FISH and IHC has yet to be reported, and will unlikely be able to answer this question due to low populations of DH/THL in the study.
Retrospective data suggest that there is no role of consolidative ASCT in MYC-positive disease in the first remission who were treated with intensive induction regimens. In a recently published multi-center retrospective study of 159 patients with DHL, there was no difference in relapse-free survival and OS between patients who received ASCT consolidation in first CR compared to those who did not. 53 However, in the subset analysis of patients who received R-CHOP, consolidative transplant was associated with improved survival compared to no trans- Similarly, in DEL, there is lack of robust prospective data validating a role in more intensive up-front CI. Small retrospective, single-center studies also suggest improved outcomes with R-EPOCH, while unplanned subset analysis from the CALGB 50303 trial suggest no difference. 54, 55 Prospective data are needed to inform an optimal induction regimen.
| RR DISEASE
At the time of progression or disease relapse, the standard treatment for transplant eligible patients remains salvage chemotherapy followed by consolidative ASCT in chemotherapy-sensitive disease (Vose 2001).
The benefit of high-dose chemotherapy and ASCT rescue in relapsed disease was originally demonstrated in the pre-rituximab era (PARMA study), where Thierry et al. demonstrated a 5-year EFS of 46% in chemotherapy-sensitive patients to chemoradiation + ASCT compared to 12% in those who received chemoradiation alone without transplant. 56 In the rituximab era, these numbers are less favorable, with the CORAL study reporting a 3-year PFS of only 37% in patients who received either R-ICE or R-DHAP prior to ASCT and only 21% in patients with prior exposure to rituximab as part of up-front CI. 3 Several specific populations with RR disease have particularly poor outcomes. Less than 20% of patients with primary progressive disease achieve long-term remissions. 30, 57 Patients who do not qualify for transplant, either after failing salvage or due to poor performance status or inadequate stem cell collection had a median OS of 3.3 months in the CORAL study. 58 In addition, patients with relapse <12 months after ASCT have a median OS of approximately 10 months. 59 Recently, the SCHOLAR-1 study combined data from two phase III clinical trials and two observational cohorts to describe the outcomes in the refractory DLBCL population. In over 636 patients with progressive disease or stable disease as the best response to at least 4 cycles of up-front CI or 2 cycles of salvage, respectively, or relapse at or within 12 months of treatment, the median OS was 6.3 months from the start of salvage treatment, with only 28% alive at 1 year. 60 With a better understanding of the heterogeneity of DLBCL, ongoing efforts are being made to refine treatment in RR disease based on disease subtypes, particularly for patients who are not eligible for transplant or who have relapsed after transplant. Tables 1 and 2 .
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| Bortezomib
Bortezomib has also been studied in the RR population. In a small study of 25 RR DLBCL patients (19 GCB subtype, 6 ABC subtype), single agents such as bortezomib had no activity, but when combined with chemotherapy had an ORR of 93% with a median OS of 10.8 months in the ABC subtype, compared to 3.4 months in the GCB subtype. 74 Confirmation in larger studies are pending. The addition of bortezomib to a salvage regimen in the relapsed setting may be beneficial for virally driven aggressive lymphomas. (28% and 25%) compared to those without DHL (57% and 61%, respectively). 16 This study also looked at DELs and reported a similarly inferior 4-year PFS (48% vs 59%, P = .049) compared to non-DEL patients, but no significant difference in the 4-year OS. In a multicenter retrospective study of 175 patients who underwent salvage chemotherapy with an intention to transplant, patients without MYC translocation had a 30% 2-year OS rate, compared to 0% in patients with MYC translocation, and 9.9% in patients with DH/THL. 76 It is unlikely that high-dose chemotherapy alone can overcome the chemoresistance conferred by unfavorable genetic translocations in the relapsed setting. Table 3 .
| Chimeric antigen receptor T-cell therapy
| Allogeneic stem cell transplant
Allogeneic stem cell transplant remains a potential curative option in the treatment of RR DLBCL, and carries the benefit of a tumor-free allograft and potential graft vs lymphoma effect. However, many patients will not qualify for transplant due to age, significant comorbidities, and poor performance status from aggressive disease and/or multiple lines of prior therapy. Historic studies have reported the long-term survival of up to 40%-50%, but in the setting of significant treatment-related mortality (30%-40%). 81 Over the past two decades, efforts to improve these outcomes have focused on reducing the intensity of conditioning regi- As such, these numbers may not reflect real-world experience, as they are vulnerable to selection bias for young and fit patients.
| Bromodomain and extraterminal motif inhibitors
Bromodomains are proteins that read the acetylation signature on histone tails and process the extent that genes will be transcribed. Once an acetyl group is found on a histone tail, the bromodomain recruits other transcrip- antitumor activity in MYC-driven animal models. 87 A recently publi- MOR208 is an Fc-enhanced monoclonal antibody against CD19, which can lead to potentiation of antibody-dependent cell-mediated toxicity and phagocytosis, as well as direct cytotoxicity. It was initially studied in RR NHL as a single agent and showed a 26% response rate in heavily pretreated, mostly rituximab refractory DLBCL patients. 93 The most common adverse events were infusion reactions and neutropenia. Most recently, data from the L-MIND study, an ongoing phase II study of MOR208 in combination with lenalidomide in RR DLBCL, were presented at the ASH 2018 annual meeting. 94 At a median follow-up of 12 months, the ORR was 58%, with 33% CR and 20% PR. In addition, 15% of patients had SD. Median DOR was not reached. Toxicities of the combination were most commonly neutropenia, thrombocytopenia, and anemia, followed by diarrhea and Stefan Klaus Barta https://orcid.org/0000-0002-3280-5271
